Clinical trials located in

Cáceres

Cáceres city is located in Spain. Currently, 13 clinical trials are being conducted in this city.

Cáceres, a city in Extremadura, Spain, boasts a rich history dating back to prehistoric times. Its well-preserved Old Town, a UNESCO World Heritage Site, showcases a blend of Roman, Islamic, Northern Gothic, and Italian Renaissance influences. Notable landmarks include the medieval walls and the Bujaco Tower. Cáceres is also renowned for its vibrant cultural scene, hosting the WOMAD festival. The city’s unique blend of architectural styles and historical depth makes it a fascinating subject of study.

  • CT-EU-00117144

    A study comparing biosimilar nivolumab and nivolumab in the treatment of resected melanoma

    The aim of this study is to test whether a new drug called ABP 206 (biosimilar nivolumab) works as well as the approved cancer drug OPDIVO® (nivolumab) in people with advanced cutaneous melanoma that has been surgically removed. The study divided people into 3 groups: one group will receive ABP 206, the second will receive real OPDIVO® approved in the US, and the third will receive the version of OPDIVO® approved in Europe. All of these medicines will be given through an intravenous drip every 4 weeks for up to 1 year, or until the cancer comes back or gets significantly worse.

    The main goal is to check whether ABP 206 (biosimilar nivolumab) is absorbed and maintained in the body in the same way as OPDIVO®. Researchers will also closely monitor how well it works, what the side effects are, and whether the body produces antibodies against it. The entire study will last approximately 13 months for each person joining.

    • Nivolumab biosimilar
    • Nivolumab
  • Evaluating ways to reduce Amivantamab infusion reactions

    This trial is designed to test how well three different medications, Dexamethasone, Montelukast, and Methotrexate, can limit the unpleasant reactions that might occur when a patient is given the drug Amivantamab by intravenous infusion with oral Lazertinib (combination therapy used to treat non-small cell lung cancer). These three drugs are given before the infusion of Amivantamab. The study will also record how long the entire infusion procedure lasts, including the administration of the pre and post infusion medications, and the percentage of people who complete the procedure within 4 hours.

    • Montelukast
    • Lazertinib
    • Methotrexate
    • Amivantamab
    • Dexamethasone
  • Study on trastuzumab deruxtecan for resistant breast cancer patients

    This clinical trial, also known as the TRANSCENDER trial, is investigating the effects of a drug called Trastuzumab Deruxtecan (T-DXd) in treating a specific type of advanced breast cancer called HER2-positive. This medicine is expected to work well in people whose disease has not responded or has had an early relapse following standard treatment. The aim is to find out how effectively this drug can slow down or possibly stop the growth of cancer cells, and how safe its use is for patients. Patients in this study will receive T-DXd intravenously every 3 weeks. The dose may be adjusted if the patient’s weight changes significantly. Treatment will continue until the cancer gets worse, side effects become too severe, or the patient decides to leave the study.

    • Trastuzumab deruxtecan
  • Advanced lung cancer treatment: comparing osimertinib with standard chemotherapy

    In this extended study, researchers are evaluating two treatment approaches for non-small cell lung cancer (NSCLC), focusing on patients who have experienced disease progression extracranially after initial treatment with osimertinib. The study aims to compare the efficacy and safety of chemotherapy combined with osimertinib versus chemotherapy combined with a placebo. Patients are randomly assigned to one of two groups. Group A receives osimertinib daily along with two chemotherapy drugs (cisplatin or carboplatin and pemetrexed) for four 21-day cycles. After these cycles, they continue taking osimertinib with maintenance pemetrexed. Group B follows a similar protocol but with a placebo instead of osimertinib. The study’s objective is to understand which treatment method better helps patients with this specific cancer profile, considering factors like genetic mutations and the presence of brain metastases. By observing the treatment’s impact on disease progression and patient safety, the researchers hope to gain insights that could improve NSCLC treatment strategies.

    • AZD9291 (Osimertinib)
    • Cisplatin
    • Carboplatin
    • Pemetrexed
  • Testing the effectiveness of a new drug compared with standard therapy in the treatment of asthma

    This medical research is a year-long study that tests a new asthma medication, called GSK3511294 (Depemokimab), against two other asthma medicines, Mepolizumab and Benralizumab. The trial is intended for teens and adults who have a severe form of asthma called ‘eosinophilic phenotype.’ The aim is to see if switching to GSK3511294 from Mepolizumab or Benralizumab keeps the severity and frequency of asthma attacks under control equally or better. Participants will keep taking their regular non-biological asthma medications throughout the trial. The study will look at the number of severe asthma attacks a patient experiences in a year, which is defined here as any worsening of asthma requiring steroids, a hospital visit, or an emergency room trip. They will also check for changes in their quality of life and their asthma control using questionnaires, and measure the capacity of their lungs with a breathing test.

    • GSK3511294 (Depemokimab)
    • Mepolizumab
    • Benralizumab
  • Research on plitidepsin effectiveness in treating COVID-19

    This research study aims to investigate the benefits and safety of a drug called plitidepsin for COVID-19 patients who have a weakened immune system and require hospital care. The study will administer the drug to some patients, while others will receive standard care, allowing researchers to assess whether plitidepsin can reduce death rates in this specific population. Throughout the study, close monitoring will be conducted to observe any changes, including side effects, serious incidents, or the necessity to discontinue the treatment.

    • Plitidepsin
  • Testing new therapy for acute myeloid leukemia treatment

    This clinical trial is all about a potential new medicine called AB8939. This study is important for people with a difficult to treat type of blood cancer known as acute myeloid leukemia (AML). AML patients who didn’t get better with their first medicines, or whose cancer came back, are the ones the study is focusing on. To begin with, doctors want to see how safe AB8939 is and how much medicine a person can tolerate. The researchers will give increasing amounts of this medicine to different groups of patients, so they can find out the best amount to give. The second part of the study will use the dose found in the first part, and see its effects on more people. The ultimate goal is to see if the medicine can reduce or eliminate the cancer in these patients.

    • AB8939- new potential medication for acute myeloid leukemia
    • azacitidine
  • Comparison of different treatments for follicular lymphoma

    This study involves comparing two treatments for a condition known as follicular or marginal zone lymphoma, both of which are types of cancer affecting lymph cells. The first treatment combines zanubrutinib with an antibody called Anti-CD20, while the second treatment involves lenalidomide and rituximab. These treatments are intended for patients who have not responded or have stopped responding to conventional treatment. One of the primary objectives of the study is to determine which treatment is more effective in preventing the cancer from progressing, referred to as progression-free survival. Additionally, the study aims to assess the impact of these treatments on the patients’ quality of life, evaluating various aspects through questionnaires related to physical and emotional well-being, symptoms, and the ability to perform normal activities.

    • Zanubrutinib
    • Obinutuzumab
    • Lenalidomide
    • Rituximab
  • Study on dazostinag & pembrolizumab for advanced solid tumors

    The purpose of this study is to test a new drug called dazostinag. A study is being conducted to see whether this drug is helpful in adults with advanced forms of solid cancer. Some people are given dazostinag alone, while others are given it with another medicine called pembrolizumab. Scientists’ focus here is on finding out whether these drugs cause any side effects, and finding out what the maximum dose is that people can take without serious side effects. The study consists of two parts, including a dose escalation phase and a dose escalation phase. In the first part, the dose of dazostinag will be gradually increased, given alone or in combination with pembrolizumab. In the second part, Dazostinag will be tested with pembrolizumab and other anticancer drugs. This section will focus on patients with specific cancers that are difficult to remove or have spread to other parts of the body.

    • Dazostinag
    • Platinum
    • Pembrolizumab
    • 5-Fluorouracil
  • Breast cancer treatment study: camizestrant vs. standard therapy

    This study is looking at a new drug called camizestrant for adults with a certain type of early breast cancer (ER+/HER2-). It compares camizestrant with standard endocrine therapies like tamoxifen and aromatase inhibitors in patients who have already received 2–5 years of endocrine therapy. The study’s focus is on preventing cancer recurrence over 60 months. About 4300 participants are involved, and the trial features an open-label design, meaning everyone knows which treatment they are receiving. The main goal is to check how well the camizestrant works in comparison to standard treatments.

    • camizestrant
    • Anastrozole
    • Letrozole
    • Exemestane
    • tamoxifen
  • Study of new drugs in acute lymphoblastic leukemia

    This clinical trial focuses on improving treatment strategies for acute lymphoblastic leukemia (ALL) in a diverse age group, from infants to young adults up to 45 years old. The study combines standard treatments with new drugs, for example, Inotuzumab Ozogamicin and Blinatumomab. The trial aims to tailor treatment to individual patient needs and reduce toxicity while maintaining treatment quality. By carefully monitoring event- and disease-free survival rates, as well as minimal residual disease responses, the trial aims to improve the standard of care for ALL and improve both survival outcomes and patient quality of life.

    • Inotuzumab Ozogamicin
    • 6-tioguanine
    • Blinatumomab
    • Imatinib
    • Dexamethasone
    • Vincristine
    • Doxorubicin
  • Exploring sacituzumab govitecan for HER2-negative breast cancer care

    This study is evaluating a new treatment for patients with a certain type of breast cancer (HER2-negative) who have not had a complete response to initial chemotherapy. Participants are randomly assigned to receive the investigational drug sacituzumab govitecan or a treatment of their physician’s choice, which may be another type of chemotherapy with capecitabinalub, carboplatin or cisplatin. The study is designed to compare the effectiveness of these approaches in preventing cancer recurrence. Patients may also receive hormone therapy if needed. Patients’ safety and response to treatment are being closely monitored throughout the study.

    • Sacituzumab govitecan
    • Carboplatin
    • Cisplatin
    • Capecitabine

See more clinical trials in other cities in Spain:

.